Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01195558
Other study ID # Pro00005099
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 2010
Est. completion date April 2030

Study information

Verified date June 2020
Source Vanda Pharmaceuticals
Contact Vanda Pharmaceuticals
Phone (202) 734-3400
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date April 2030
Est. primary completion date April 2030
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria.

2. Subjects must be blind.

3. Subjects must have some self-described problem with sleep or daytime sleepiness.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Data collection on blindness and sleep problems
Data related to degree of vision impairment and sleep problems is collected through a phone or web survey

Locations

Country Name City State
United States Vanda Pharmaceuticals Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Vanda Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of blind participants ongoing
Secondary Sleep/wake disruptions ongoing